Literature DB >> 19109147

Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo.

Lars T van der Veken1, Miriam Coccoris, Erwin Swart, J H Frederik Falkenburg, Ton N Schumacher, Mirjam H M Heemskerk.   

Abstract

The successful application of T cell-based immunotherapeutic applications depends on the availability of large numbers of T cells with the desired Ag specificity and phenotypic characteristics. Engineering of TCR-transferred T lymphocytes is an attractive strategy to obtain sufficient T cells with an Ag specificity of choice. However, the introduction of additional TCR chains into T cells leads to the generation of T cells with unknown specificity, due to the formation of mixed dimers between the endogenous and introduced TCR chains. The formation of such potentially autoaggressive T cells may be prevented by using gammadelta T cells as recipient cells, but the in vivo activity of such TCR-engineered gammadelta T cells has not been established. In the present study, we have investigated the in vivo functionality of TCR-transduced gammadelta T cells, in particular their Ag specific proliferative capacity, Ag specific reactivity, in vivo persistence, and their capacity to mount recall responses. The results demonstrate that alphabeta TCR engineering of gammadelta T cells forms a feasible strategy to generate Ag-specific effector T cells that do not express mixed TCR dimers. In view of increasing concerns on the potential autoimmune consequences of mixed TCR dimer formation, the testing of alphabeta TCR engineered gammadelta T cells in clinical trials seems warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19109147     DOI: 10.4049/jimmunol.182.1.164

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Mixed T cell receptor dimers harbor potentially harmful neoreactivity.

Authors:  Marleen M van Loenen; Renate de Boer; Avital L Amir; Renate S Hagedoorn; Gerdien L Volbeda; Roelof Willemze; Johannes J van Rood; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

Review 2.  Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.

Authors:  Hamid Reza Mirzaei; Hamed Mirzaei; Sang Yun Lee; Jamshid Hadjati; Brian G Till
Journal:  Cancer Lett       Date:  2016-07-05       Impact factor: 8.679

Review 3.  Adoptive T cell therapy of cancer.

Authors:  Malcolm K Brenner; Helen E Heslop
Journal:  Curr Opin Immunol       Date:  2010-02-17       Impact factor: 7.486

4.  Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.

Authors:  D H Aggen; A S Chervin; T M Schmitt; B Engels; J D Stone; S A Richman; K H Piepenbrink; B M Baker; P D Greenberg; H Schreiber; D M Kranz
Journal:  Gene Ther       Date:  2011-07-14       Impact factor: 5.250

5.  T-cell receptor gene transfer for the treatment of leukemia and other tumors.

Authors:  Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2010-01       Impact factor: 9.941

Review 6.  Treating cancer with genetically engineered T cells.

Authors:  Tristen S Park; Steven A Rosenberg; Richard A Morgan
Journal:  Trends Biotechnol       Date:  2011-06-12       Impact factor: 19.536

Review 7.  Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.

Authors:  Marie Bleakley; Cameron J Turtle; Stanley R Riddell
Journal:  Expert Rev Hematol       Date:  2012-08       Impact factor: 2.929

Review 8.  Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy.

Authors:  Cameron J Turtle; Stanley R Riddell
Journal:  Curr Opin Immunol       Date:  2011-01-14       Impact factor: 7.486

9.  T Cell Reprogramming Against Cancer.

Authors:  Samuel G Katz; Peter M Rabinovich
Journal:  Methods Mol Biol       Date:  2020

Review 10.  Potential of human γδ T cells for immunotherapy of osteosarcoma.

Authors:  Zhaoxu Li
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.